Identification of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration

• Main Authors: Horacio Gomez-Acevedo, Yuemeng Dai, Graham Strub, Carrie Shawber, June K. Wu, Gresham T. Richter
• Format: Article
• Language: English
• Published: Nature Publishing Group 2020-02-01
• Series: Scientific Reports
• Online Access: https://doi.org/10.1038/s41598-020-60025-2

Abstract Infantile hemangiomas (IHs) are the most common benign tumors in early childhood. They show a distinctive mechanism of tumor growth in which a rapid proliferative phase is followed by a regression phase (involution). Propranolol is an approved treatment for IHs, but its mechanism of action remains unclear. We integrated and harmonized microRNA and mRNA transcriptome data from newly generated microarray data on IHs with publicly available data on toxicological transcriptomics from propranolol exposure, and with microRNA data from IHs and propranolol exposure. We identified subsets of putative biomarkers for proliferation and involution as well as a small set of putative biomarkers for propranolol’s mechanism of action for IHs, namely EPAS1, LASP1, SLC25A23, MYO1B, and ALDH1A1. Based on our integrative data approach and confirmatory experiments, we concluded that hypoxia in IHs is regulated by EPAS1 (HIF-2α) instead of HIF-1α, and also that propranolol-induced apoptosis in endothelial cells may occur via mitochondrial stress.